KR20240064747A - 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료 - Google Patents

모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료 Download PDF

Info

Publication number
KR20240064747A
KR20240064747A KR1020247014382A KR20247014382A KR20240064747A KR 20240064747 A KR20240064747 A KR 20240064747A KR 1020247014382 A KR1020247014382 A KR 1020247014382A KR 20247014382 A KR20247014382 A KR 20247014382A KR 20240064747 A KR20240064747 A KR 20240064747A
Authority
KR
South Korea
Prior art keywords
minoxidil
range
hair
concentration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247014382A
Other languages
English (en)
Korean (ko)
Inventor
로드니 싱클레어
Original Assignee
삼손 클리니컬 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by 삼손 클리니컬 피티와이 엘티디 filed Critical 삼손 클리니컬 피티와이 엘티디
Publication of KR20240064747A publication Critical patent/KR20240064747A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
KR1020247014382A 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료 Ceased KR20240064747A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
AU2017902722 2017-07-12
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA
KR1020207002802A KR102663164B1 (ko) 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002802A Division KR102663164B1 (ko) 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Publications (1)

Publication Number Publication Date
KR20240064747A true KR20240064747A (ko) 2024-05-13

Family

ID=65001077

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247014382A Ceased KR20240064747A (ko) 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
KR1020207002802A Active KR102663164B1 (ko) 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002802A Active KR102663164B1 (ko) 2017-07-12 2018-07-12 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Country Status (10)

Country Link
US (2) US20190269684A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651769B1 (cg-RX-API-DMAC7.html)
JP (2) JP7191927B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240064747A (cg-RX-API-DMAC7.html)
CN (1) CN111065396A (cg-RX-API-DMAC7.html)
AU (2) AU2018250398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069336A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909395T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202000124PA (cg-RX-API-DMAC7.html)
WO (1) WO2019010535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
WO2021178871A1 (en) 2020-03-05 2021-09-10 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
CN112691187B (zh) * 2020-12-30 2021-12-21 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법
EP4539816A4 (en) * 2023-09-01 2025-07-23 Follea Int COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA
KR20260065905A (ko) * 2023-09-08 2026-05-11 수조우 킨터 제약회사(주) 안드로겐 수용체 억제제/길항제를 함유하는 약학 조성물, 방법 및 용도
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation
WO2026062695A1 (en) * 2024-09-17 2026-03-26 Shah Atul K Toothpaste for body disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
CN1838969A (zh) * 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
JP2009091325A (ja) * 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
EP2344198B1 (en) * 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
NZ732075A (en) * 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Also Published As

Publication number Publication date
AU2018250398B2 (en) 2019-02-28
WO2019010535A1 (en) 2019-01-17
AU2019203438A1 (en) 2019-06-06
AU2018250398A1 (en) 2019-01-31
CN111065396A (zh) 2020-04-24
ES2909395T3 (es) 2022-05-06
JP2023016964A (ja) 2023-02-02
CA3069336A1 (en) 2019-01-17
SG11202000124PA (en) 2020-02-27
US20190269684A1 (en) 2019-09-05
EP3651769A1 (en) 2020-05-20
JP7191927B2 (ja) 2022-12-19
EP3651769B1 (en) 2022-01-05
US20250064807A1 (en) 2025-02-27
KR102663164B1 (ko) 2024-05-07
NZ760579A (en) 2024-09-27
EP3651769A4 (en) 2021-04-21
JP2020527146A (ja) 2020-09-03
BR112020000508A2 (pt) 2020-07-14
KR20200028403A (ko) 2020-03-16

Similar Documents

Publication Publication Date Title
KR102663164B1 (ko) 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
JP2022508317A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20080038355A1 (en) Bioadhesive dosage form of steroids
US20250381192A1 (en) Treatment of Autoimmune Disease
JP2003533465A (ja) 迅速崩壊固体経口投与形態
EA034288B1 (ru) Система доставки лекарственного средства
US20110086070A1 (en) Orally disintegrating compositions of rhein or diacerein
KR20200040761A (ko) 코티코트로핀 방출 인자 수용체 길항제
JP2021121645A (ja) １５β−ヒドロキシ−酢酸オサテロンの結晶多形
AU2022200479A1 (en) Treatment of autoimmune disease
CN105395504B (zh) 一种盐酸氟桂利嗪骨架缓释片及其制备方法
WO2021171318A1 (en) Transmucosal pharmaceutical composition of levocetirizine
BR122025006573A2 (pt) Composição dispersível
HK40018518B (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
HK40018518A (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível
WO2026076270A1 (en) Oral mucosal formulations of aspirin
HU204997B (en) Process for producing carrier system suitable for ensuring controlled biological access to dihydropyridines, as well as new oral dosage form ensuring improved biological access
JP2022000473A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
BR112014014131B1 (pt) formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato e processos para produzir as mesmas
Maroni et al. Pharmaceutical formulations of nimesulide

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240429

Application number text: 1020207002802

Filing date: 20200129

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240527

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240626

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D